Development
Tarsus Pharmaceuticals, Inc.
TARS
$41.64
$0.491.19%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -208.13% | -73.91% | -447.17% | -15.72% | 8.43% |
| Total Depreciation and Amortization | 254.08% | 159.57% | 97.83% | 153.66% | 145.00% |
| Total Amortization of Deferred Charges | 42.31% | 7.45% | 12.20% | 47.27% | -- |
| Total Other Non-Cash Items | 99.51% | 37.30% | 4.68% | -17.18% | -7.12% |
| Change in Net Operating Assets | -3,402.35% | 3,093.18% | 214.90% | -186.27% | 129.73% |
| Cash from Operations | -261.73% | -73.89% | -459.43% | -43.73% | 10.29% |
| Capital Expenditure | 100.00% | -290.63% | -545.08% | -111.18% | 53.65% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 120.50% | 183.71% | -- | -- | -- |
| Cash from Investing | 120.47% | 182.92% | 52,634.43% | 7,114.91% | -31,731.75% |
| Total Debt Issued | -- | -- | -- | -75.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7,384.85% | -- | -99.32% | -- | 15.28% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | 7,384.85% | 77,227.21% | -99.32% | -73.79% | 456.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.24% | 258.02% | -42.04% | -253.97% | -684.58% |